Glaukos Corp (GKOS) USD0.001
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company that is focused on developing therapies for the treatment of glaucoma, corneal disorders, and retinal disease. The Company’s products are designed to treat mild-to-moderate open-angle glaucoma, the iStent, the iStent inject, and the iStent inject W. The Company’s Micro-Invasive Glaucoma Surgery (MIGS) serves as an alternative to the traditional glaucoma treatment paradigm. It offers bio-activated pharmaceutical therapy for the treatment of corneal disorder and keratoconus. It is also developing a pipeline of surgical devices, sustained pharmaceutical therapies, implantable biosensors intended to treat glaucoma progression, corneal disorders such as keratoconus, dry eye, refractive vision correction, retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.